Epigenetic oncogenesis, biomarkers and emerging chemotherapeutics for breast cancer

Ayipo, Yusuf Oloruntoyin; Ajiboye, Abdulfatai Temitope; Osunniran, Wahab Adesina; Jimoh, Abdulgafar Olayiwola; Mordi, Mohd Nizam

doi:10.1016/j.bbagrm.2022.194873

Cited by 9 publications

(5 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liraglutide is a well-known diabetes drug, but it can act as a DNMTi in breast cancer in vitro and in vivo in Ehnlich mouse tumor models. The results revealed that liraglutide reduced cell viability, migration, and DNMT activity [64]. It is effective in promoting anti-proliferative activity and deteriorating migration and motility of mesenchymal breast cancer cell lines.…”

Section: Dnmti In Breast Cancermentioning

confidence: 95%

Epigenetic Regulation in Breast Cancer: Insights on Epidrugs

Kim

Kwon

et al. 2023

Epigenomes

View full text Add to dashboard Cite

Breast cancer remains a common cause of cancer-related death in women. Therefore, further studies are necessary for the comprehension of breast cancer and the revolution of breast cancer treatment. Cancer is a heterogeneous disease that results from epigenetic alterations in normal cells. Aberrant epigenetic regulation is strongly associated with the development of breast cancer. Current therapeutic approaches target epigenetic alterations rather than genetic mutations due to their reversibility. The formation and maintenance of epigenetic changes depend on specific enzymes, including DNA methyltransferases and histone deacetylases, which are promising targets for epigenetic-based therapy. Epidrugs target different epigenetic alterations, including DNA methylation, histone acetylation, and histone methylation, which can restore normal cellular memory in cancerous diseases. Epigenetic-targeted therapy using epidrugs has anti-tumor effects on malignancies, including breast cancer. This review focuses on the importance of epigenetic regulation and the clinical implications of epidrugs in breast cancer.

show abstract

Section: Dnmti In Breast Cancermentioning

confidence: 95%

Epigenetic Regulation in Breast Cancer: Insights on Epidrugs

Kim

Kwon

et al. 2023

Epigenomes

View full text Add to dashboard Cite

show abstract

“…Ultimately, modifications in the chromatin structure involve the binding of MBPs and DNMTs to histone deacetylase (HDAC) and histone methyltransferase (HMT) complexes. 2 The effects of DNA methylation in cancer cells were initially observed with the loss of methylation in repetitive regions of specific genes, including tumor antigens, oncogenes, and metastasis-associated genes, known as global genomic DNA hypomethylation. This phenomenon has been further associated with chromosomal instability in cancer.…”

Section: Major Epigenetic Dysregulations Prominent In Breast Cancer D...mentioning

confidence: 99%

“…1 While the importance of genetic background in this type of cancer is evident from family history, recent studies have revealed the significant contributions of various epigenetic modifications to tumorigenesis. 2 Similar to the majority of cancers, alterations in epigenetic mechanisms in breast cancer, characterized by its complex and high intratumor heterogeneity, have emerged as key hallmarks of the disease. These alterations have also prompted the exploration of new strategies to modulate the dysregulated epigenome and overcome acquired resistance to therapeutic agents.…”

Section: Introductionmentioning

confidence: 99%

Current Advances in Breast Cancer: Implications for Developing New Treatment Strategies Through Epi-Drugs on the Road to Modifying the Epigenome

Kenanoğlu

2023

J Clin Pract Res

View full text Add to dashboard Cite

Breast cancer is one of the most commonly diagnosed neoplasms affecting women worldwide, and it remains a leading cause of both mortality and morbidity. While genetic predisposition plays a critical role in the development of this neoplasm, significant epigenetic dysregulations accompany existing variants. The emergence of acquired drug resistance to current chemotherapeutics poses a significant challenge in managing therapy. However, progress has been made in developing novel agents that directly target epigenetic modifications. These agents, called "epi-drugs, " can be used alone in the clinic or in combination with current treatment regimens, offering the potential to create diversified effects on the disease's predictive process. Within the scope of this review, general information about the major epigenetic dysregulations in breast cancer will be provided, and their effects on the molecular mechanisms in the carcinogenesis process will be discussed. Furthermore, current treatment approaches for breast cancer will be explored, classifying these epi-drugs, such as DNA methyltransferase inhibitors (DNMTIs), histone deacetylase inhibitors (HDA-CIs), histone acetyltransferases (HATIs), and others that have been developed to target these mechanisms. Predictions regarding the future prospects of these epi-drugs are highlighted, and their contributions to the field of personalized medicine are emphasized based on the results obtained from clinical studies.

show abstract

“…Its etiology is largely unknown and believed to be multifactorial [2], genetic [3,4], auto-immune [5], hemoparasitic [6,7], and viral diseases [8]. The exact mechanism by which chronic inflammatory processes induce oncogenesis is still unclear, but persistent immunosuppression [9], epigenetic events [10], and relevant association with immunosenescence [11] have all been associated with neoplasm developments.…”

Section: Introductionmentioning

confidence: 99%

Current Challenges in the Association between Canine Leishmaniasis and Malignant Disorders

Silva Ribeiro,

de Oliveira Cardoso,

Lucia Abreu-Silva

et al. 2024

Leishmania Parasites - Epidemiology, Immunopathology and Hosts

View full text Add to dashboard Cite

Neoplasms in dogs are estimated to account for up to 83% of all canine malignancies, while canine leishmaniasis is endemic and highly incident in areas like Brazil, east Africa, and India. The worldwide incidence of both diseases may indicate the presence of these two pathologies in the same tissue sample as eventual cases. However, a relationship between leishmaniasis and malignant disorders has been postulated in human and veterinary medicine. Depending on several direct or indirect factors, leishmaniasis can affect the clinical manifestation, diagnosis, therapeutic protocols, and the outcome of various malignant disorders. In addition, the similarity of the clinical presentation of cutaneous or visceral leishmaniasis with the clinical signs observed in many tumors may lead to misdiagnosis. Clinical cases of co-localization of Leishmania parasites and tumor cells in dogs were more associated with transmissible venereal tumors than histiocytic tumors, non-histiocytic lymphoma, or squamous cell carcinoma. This chapter reviews the circumstances involving canine leishmaniasis and malignant disorders, and the current challenge that the association between them represents to misdiagnosis or tumor-promoting potential of leishmaniasis, providing an overview of dog cases.

show abstract

Epigenetic oncogenesis, biomarkers and emerging chemotherapeutics for breast cancer

Cited by 9 publications

References 94 publications

Epigenetic Regulation in Breast Cancer: Insights on Epidrugs

Epigenetic Regulation in Breast Cancer: Insights on Epidrugs

Current Advances in Breast Cancer: Implications for Developing New Treatment Strategies Through Epi-Drugs on the Road to Modifying the Epigenome

Current Challenges in the Association between Canine Leishmaniasis and Malignant Disorders

Contact Info

Product

Resources

About